QIAGEN Expands QIAcuity Gene Expression Portfolio to Accelerate Digital PCR Adoption Across Research and Biopharma

(Moderate)

(Neutral)

Key Terms

digital pcr technical

Digital PCR is a laboratory method that counts individual copies of DNA or RNA by dividing a sample into many tiny, separate reactions and detecting which ones contain the target sequence, like counting coins in separate slots. It gives a very precise, sensitive measure of genetic material, making it valuable for diagnostics, drug development, quality control, and tracking treatment response — factors that can affect regulatory approval, market adoption, and a company’s revenue prospects.

dpcr technical

Digital PCR (dPCR) is a laboratory method that counts individual DNA or RNA molecules by splitting a sample into many tiny reactions and seeing which ones light up, similar to counting marbles in many small cups to get an exact total. It matters to investors because it can detect very small amounts of genetic material with high precision, which improves diagnostic tests, quality control, and clinical trial measurements—factors that can affect a biotech company’s product value and regulatory prospects.

qpcr technical

qPCR (quantitative polymerase chain reaction) is a laboratory test that makes many copies of a specific segment of genetic material and measures how much of that material is present, producing a fast, numerical readout. Think of it like a photocopier that both multiplies and counts a particular page so you know exactly how many copies exist. Investors care because qPCR is widely used for diagnostics, regulatory testing and product validation—results can affect clinical progress, sales and regulatory approvals, making it a practical indicator of commercial and scientific momentum.

cell and gene therapy medical

Therapies that use living cells or altered genes to treat or cure disease by repairing, replacing or reprogramming parts of the body; think of it as swapping or reprogramming malfunctioning hardware or software inside the body. Investors watch these treatments closely because they can command high prices and offer one-time or long-lasting benefits, but they also carry big development costs, complex manufacturing and regulatory risks that can cause large swings in a company’s value.

residual dna testing technical

Residual DNA testing measures tiny amounts of genetic material left behind from the cells used to make a biological drug or vaccine after manufacturing and purification. Investors care because levels of leftover DNA are a key safety and quality metric regulators watch; high or inconsistent results can trigger additional testing, production delays, costly fixes, or regulatory scrutiny, similar to finding crumbs after cleaning that indicate a job was incomplete.

host-cell dna medical

Genetic material left over from the cells used to produce a biological drug or vaccine; during manufacturing the host cells that make the medicine can shed fragments of their DNA that must be removed or reduced. Investors care because regulators require strict limits and testing for this leftover DNA—like finding sawdust in finished furniture, it signals manufacturing cleanliness and can affect approval, production costs, recalls, or product delays.

workflow automation technical

Workflow automation is the use of technology to perform repetitive tasks automatically, reducing the need for manual effort. It is similar to setting a machine to handle routine chores so that people can focus on more important activities. For investors, it means faster, more efficient processes that can improve decision-making and reduce errors across various business functions.

nanoplate technical

A nanoplate is an extremely thin, flat particle measured at the scale of billionths of a meter, like a microscopic tile or a sheet of paper compared to a book. In products, nanoplate shape can change strength, conductivity, drug delivery or how materials mix, so investors care because it can affect a product’s performance, manufacturing cost, safety profile and regulatory review—factors that influence market adoption and returns.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

06/15/2026 - 01:30 AM

Planned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology application areas

Expanded Cell and Gene Therapy offerings and workflow automation capabilities strengthen the QIAcuity digital PCR ecosystem

New software capabilities support standardized analysis and reporting across digital PCR workflows

VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)-- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across life sciences and biopharma applications.

As researchers increasingly seek higher sensitivity, greater precision and improved multiplexing capabilities, dPCR is gaining adoption across a growing range of applications traditionally served by qPCR technologies. QIAGEN is expanding the QIAcuity ecosystem with new gene expression solutions, workflow automation and analysis capabilities designed to support broader adoption of digital PCR across research and biopharma applications.

"Gene expression represents one of the largest application areas in molecular biology and a significant opportunity for digital PCR," said Thierry Bernard, CEO of QIAGEN. "By expanding the QIAcuity ecosystem with new assays, enhanced multiplexing capabilities and workflow solutions, we are helping customers apply digital PCR to a broader range of research and biopharma applications."

The latest additions to the QIAcuity portfolio include:

New gene expression solutions for dPCR: QIAGEN plans to expand its portfolio later in 2026 with new QIAcuity Gene Expression Assays designed to support gene expression analysis across human, mouse and rat research applications. The company also plans to introduce the new QIAcuity OneStep High Multiplex Probe PCR Kit, enabling analysis of up to 12 RNA targets in a single reaction and helping researchers generate richer biological insights while reducing sample consumption, hands-on time and workflow complexity. These additions complement QIAGEN's GeneGlobe platform, providing access to more than 10 million predesigned assays as well as custom assay design capabilities for specialized research needs.

Expanded Cell and Gene Therapy quality control portfolio: Building on its established portfolio of dPCR solutions for Cell and Gene Therapy applications, QIAGEN is expanding its residual DNA testing offering to support additional producer cell systems, including Sf9/Baculovirus, Pichia pastoris, Vero and Mouse. The portfolio also includes the recently launched QIAcuity HEK293 resDNA Sizing Kit, which enables precise measurement of both host-cell DNA concentration and fragment size distribution to support biopharmaceutical development and manufacturing workflows.

Enhanced automated analysis and reporting with QIAcuity Software 3.5: Scheduled for release later this month, QIAcuity Software 3.5 introduces advanced analysis templates and automated reporting capabilities that enable users to define analysis and reporting parameters before a run begins. The software helps laboratories automate and standardize data interpretation and reporting through predefined analysis and reporting templates. By automatically applying analysis parameters and generating reports after run completion, laboratories can reduce manual review steps while improving traceability, consistency and operational efficiency, particularly in larger-scale and regulated workflows.

Expanded laboratory automation through Hamilton integration: In addition to the automated analysis and reporting capabilities introduced with QIAcuity Software 3.5, customers can build on QIAGEN's collaboration with Hamilton to automate QIAcuity dPCR nanoplate setup and handling workflows, including sample preparation, nanoplate filling and sealing. Integration with robotic systems enables fully automated workflows from assay setup through data analysis, helping high-throughput laboratories increase productivity while minimizing risks associated with manual handling.

QIAcuity adoption continues to grow across academia, biopharma and clinical research, with over 3,200 cumulative placements worldwide since launch. More than 400 customers now operate multiple QIAcuity instruments, while over 1,100 scientific publications reference the platform. The continued expansion of the QIAcuity ecosystem reflects QIAGEN's strategy to support customers throughout the transition from qPCR to dPCR and toward increasingly scalable, automated and standardized dPCR workflows.

Additional details on QIAGEN's QIAcuity dPCR strategy, technology roadmap and growth opportunities will be discussed during the upcoming QIAcuity Deep Dive event on Monday, June 15, 2026. The event will be webcast and available to investors, analysts and other interested stakeholders. More information is available at https://corporate.qiagen.com/English/investor-relations/events-and-presentations/QIAGEN-Deep-Dive--QIAcuity-digital-PCR/default.aspx.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Source: QIAGEN N.V.

Category: PCR & Genomics